Astria Therapeutics (NASDAQ:ATXS - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company's stock. HC Wainwright's target price would suggest a potential upside of 114.48% from the company's previous close.
Separately, Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $25.60.
Read Our Latest Research Report on ATXS
Astria Therapeutics Price Performance
NASDAQ:ATXS traded up $0.01 during trading hours on Monday, hitting $7.46. The company's stock had a trading volume of 374,964 shares, compared to its average volume of 250,152. Astria Therapeutics has a twelve month low of $6.94 and a twelve month high of $16.90. The stock has a fifty day simple moving average of $9.77 and a 200-day simple moving average of $10.69. The company has a market capitalization of $421.00 million, a P/E ratio of -3.57 and a beta of 0.70.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ATXS. Quest Partners LLC raised its stake in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares during the last quarter. PDT Partners LLC acquired a new position in Astria Therapeutics during the 3rd quarter worth approximately $140,000. SG Americas Securities LLC bought a new position in Astria Therapeutics in the third quarter worth approximately $155,000. Hsbc Holdings PLC acquired a new stake in Astria Therapeutics in the second quarter valued at approximately $171,000. Finally, Intech Investment Management LLC bought a new stake in shares of Astria Therapeutics during the third quarter valued at approximately $228,000. Institutional investors own 98.98% of the company's stock.
Astria Therapeutics Company Profile
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Recommended Stories
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
